Sho Morioka

2.4k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Sho Morioka is a scholar working on Immunology, Molecular Biology and Cancer Research. According to data from OpenAlex, Sho Morioka has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 8 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Sho Morioka's work include Phagocytosis and Immune Regulation (11 papers), NF-κB Signaling Pathways (8 papers) and Immune Response and Inflammation (5 papers). Sho Morioka is often cited by papers focused on Phagocytosis and Immune Regulation (11 papers), NF-κB Signaling Pathways (8 papers) and Immune Response and Inflammation (5 papers). Sho Morioka collaborates with scholars based in United States, Japan and Belgium. Sho Morioka's co-authors include Kodi S. Ravichandran, Jun Ninomiya‐Tsuji, Christian Maueröder, Justin S. A. Perry, Christopher B. Medina, Kunihiro Matsumoto, Emily Omori, Brady Barron, Sanja Arandjelovic and Michael H. Raymond and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Sho Morioka

23 papers receiving 1.7k citations

Hit Papers

Metabolites released from... 2020 2026 2022 2024 2020 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sho Morioka United States 15 945 773 279 229 199 24 1.7k
Seung‐Yoon Park South Korea 24 614 0.6× 878 1.1× 434 1.6× 352 1.5× 206 1.0× 57 1.8k
Ghada Alsaleh France 22 533 0.6× 824 1.1× 463 1.7× 226 1.0× 214 1.1× 36 1.8k
H. Eric Canada 14 539 0.6× 752 1.0× 345 1.2× 176 0.8× 222 1.1× 21 1.5k
Emily F. Mason United States 12 1.2k 1.3× 833 1.1× 519 1.9× 175 0.8× 310 1.6× 32 2.3k
Qiujing Yu China 18 541 0.6× 941 1.2× 447 1.6× 171 0.7× 257 1.3× 30 1.7k
Fabrizio Antonangeli Italy 22 736 0.8× 663 0.9× 260 0.9× 237 1.0× 135 0.7× 38 1.7k
Jacques Behmoaras United Kingdom 22 502 0.5× 808 1.0× 142 0.5× 184 0.8× 165 0.8× 57 1.6k
Fei He China 18 543 0.6× 766 1.0× 276 1.0× 89 0.4× 137 0.7× 33 1.4k
Askar M. Akimzhanov United States 16 1.4k 1.5× 669 0.9× 194 0.7× 193 0.8× 124 0.6× 25 2.2k

Countries citing papers authored by Sho Morioka

Since Specialization
Citations

This map shows the geographic impact of Sho Morioka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sho Morioka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sho Morioka more than expected).

Fields of papers citing papers by Sho Morioka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sho Morioka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sho Morioka. The network helps show where Sho Morioka may publish in the future.

Co-authorship network of co-authors of Sho Morioka

This figure shows the co-authorship network connecting the top 25 collaborators of Sho Morioka. A scholar is included among the top collaborators of Sho Morioka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sho Morioka. Sho Morioka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morioka, Sho, Seigo Sanoh, Yuji Ishida, et al.. (2025). Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease. Archives of Toxicology. 99(5). 2133–2142.
2.
Ishida, Yuji, Sho Morioka, Chihiro Yamasaki, et al.. (2023). Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response. JCI Insight. 8(9). 7 indexed citations
3.
Raymond, Michael H., Andrew J. Davidson, Yi Shen, et al.. (2022). Live cell tracking of macrophage efferocytosis during Drosophila embryo development in vivo. Science. 375(6585). 1182–1187. 44 indexed citations
4.
Morioka, Sho, Turan Tufan, Shinji Tanaka, et al.. (2022). Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation. Cell. 185(26). 4887–4903.e17. 38 indexed citations
5.
Medina, Christopher B., Parul Mehrotra, Sanja Arandjelovic, et al.. (2020). Metabolites released from apoptotic cells act as tissue messengers. Nature. 580(7801). 130–135. 345 indexed citations breakdown →
6.
Perry, Justin S. A., Sho Morioka, Christopher B. Medina, et al.. (2019). Interpreting an apoptotic corpse as anti-inflammatory involves a chloride sensing pathway. Nature Cell Biology. 21(12). 1532–1543. 73 indexed citations
7.
Rival, Claudia, Wenhao Xu, Laura S. Shankman, et al.. (2019). Phosphatidylserine on viable sperm and phagocytic machinery in oocytes regulate mammalian fertilization. Nature Communications. 10(1). 4456–4456. 57 indexed citations
8.
Morioka, Sho, Christian Maueröder, & Kodi S. Ravichandran. (2019). Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology. Immunity. 50(5). 1149–1162. 260 indexed citations
9.
Perry, Justin S. A., Sho Morioka, Christopher B. Medina, Michael H. Raymond, & Kodi S. Ravichandran. (2019). Abstract A098: SLC12A2 as a novel “brake” on immunogenic apoptotic cell clearance. Cancer Immunology Research. 7(2_Supplement). A098–A098. 1 indexed citations
10.
Morioka, Sho, Justin S. A. Perry, Michael H. Raymond, et al.. (2018). Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 563(7733). 714–718. 253 indexed citations
11.
Michaels, Alex D., Timothy E. Newhook, Sara J. Adair, et al.. (2017). CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clinical Cancer Research. 24(6). 1415–1425. 81 indexed citations
12.
Morioka, Sho, et al.. (2017). TAK1 regulates resident macrophages by protecting lysosomal integrity. Cell Death and Disease. 8(2). e2598–e2598. 13 indexed citations
14.
Morioka, Sho, Giichi Takaesu, Nagendran Muthusamy, et al.. (2016). TAK1 determines susceptibility to endoplasmic reticulum stress and leptin resistance in the hypothalamus. Journal of Cell Science. 129(9). 1855–1865. 11 indexed citations
15.
Morioka, Sho, Kimie Sai, Emily Omori, et al.. (2016). TAK1 regulates hepatic lipid homeostasis through SREBP. Oncogene. 35(29). 3829–3838. 23 indexed citations
16.
Morioka, Sho, et al.. (2014). Activated Macrophage Survival Is Coordinated by TAK1 Binding Proteins. PLoS ONE. 9(4). e94982–e94982. 21 indexed citations
17.
Ninomiya‐Tsuji, Jun, et al.. (2014). TAK1 control of cell death. Cell Death and Differentiation. 21(11). 1667–1676. 221 indexed citations
18.
Ikeda, Yuka, Sho Morioka, Kunihiro Matsumoto, & Jun Ninomiya‐Tsuji. (2014). TAK1 Binding Protein 2 Is Essential for Liver Protection from Stressors. PLoS ONE. 9(2). e88037–e88037. 10 indexed citations
19.
Morioka, Sho, Emily Omori, Toshitaka Kajino, et al.. (2009). TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene. 28(23). 2257–2265. 33 indexed citations
20.
Omori, Emily, Sho Morioka, Kunihiro Matsumoto, & Jun Ninomiya‐Tsuji. (2008). TAK1 Regulates Reactive Oxygen Species and Cell Death in Keratinocytes, Which Is Essential for Skin Integrity. Journal of Biological Chemistry. 283(38). 26161–26168. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026